DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for Lancet and Lancing Devices 2017 - MedCore" report to their offering.
The lancet and lancing device market can be segmented by setting, yielding two segments: personal and professional. In 2016, the largest segment in the total lancet and lancing device market was the personal segment. Personal lancets and lancing devices are used by individuals who use personal meters to perform self-monitoring blood glucose (SMBG) on a daily basis.
CMS competitive bidding had a significant impact on the personal lancet and lancing device market after substantial reimbursement cuts in July 2013 and July 2016, respectively.
Lancet reuse is also a limiter of growth in the personal segment. The professional market comprises safety lancets, which are used by clinicians and staff in the hospital or long term care settings to measure the blood glucose levels of their diabetic patients. Safety lancets are necessary to avoid the risk of needlestick injuries and the spread of blood-borne pathogens.
Key Topics Covered:
1. Executive Summary
U.S. Diabetes Monitoring, Treatment And Drug Delivery Market Overview
Procedure Codes Investigated
Key Report Updates
2. Disease Overview
2.1.1 Types Of Diabetes
2.1.2 Diabetes Complications
2.1.3 Risk Factors Associated With Type 1 And Type 2 Diabetes
2.1.4 Signs And Symptoms
2.1.5 Diabetes Monitoring
2.1.7 Drug Delivery Systems
3. Lancet And Lancing Device Market
3.2 Market Overview
3.3 Market Analysis And Forecast
3.3.1 Total Lancet And Lancing Device Market
184.108.40.206 Personal Lancet And Lancing Device Market
220.127.116.11 Professional Lancet And Lancing Device Market
3.4 Drivers And Limiters
3.4.1 Market Drivers
3.4.2 Market Limiters
3.5 Competitive Market Share Analysis
- Novo Nordisk
- Eli Lilly
- Johnson & Johnson
- Becton Dickinson
- Trividia Health
- Nova Biomedical
For more information about this report visit http://www.researchandmarkets.com/research/pj3lcm/us_market_report